Gilead Sciences
GILD
$63.06
Share price
-1.89%
Change (1 day)
-18.86%
Change (1 year)
Categories
P/S ratio for Gilead Sciences (GILD)
P/S ratio as of June 2024 (TTM): 2.92
According to Gilead Sciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.91707. At the end of 2023 the company had a P/S ratio of 3.72.
P/S ratio history for Gilead Sciences from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 3.72 | -5.68% |
| 2022 | 3.95 | 18.36% |
| 2021 | 3.33 | 12.73% |
| 2020 | 2.96 | -19.28% |
| 2019 | 3.66 | 1.12% |
| 2018 | 3.62 | 1.1% |
| 2017 | 3.58 | 15.47% |
| 2016 | 3.10 | -29.58% |
| 2015 | 4.41 | -22.34% |
| 2014 | 5.68 | -44.82% |
| 2013 | 10.3 | 78.9% |
| 2012 | 5.75 | 56.83% |
| 2011 | 3.67 | 0.28% |
| 2010 | 3.66 | -34.16% |
| 2009 | 5.55 | -36.37% |
| 2008 | 8.73 | -13.63% |
| 2007 | 10.1 | 2.11% |
| 2006 | 9.89 | -16.96% |
| 2005 | 11.9 | 0.5% |
| 2004 | 11.9 | -17.21% |
| 2003 | 14.3 | -0.5% |
| 2002 | 14.4 | -46.96% |
| 2001 | 27.1 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.92 | 34.30% | 🇺🇸 USA |
 Pfizer PFE | 2.78 | -4.87% | 🇺🇸 USA |
 AbbVie ABBV | 5.51 | 88.81% | 🇺🇸 USA |
 Eli Lilly LLY | 23.4 | 702.47% | 🇺🇸 USA |
 Amgen AMGN | 5.51 | 88.85% | 🇺🇸 USA |
 Biogen BIIB | 3.41 | 16.97% | 🇺🇸 USA |
 Illumina ILMN | 3.87 | 32.57% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 12.0 | 311.43% | 🇺🇸 USA |
 Merck MRK | 5.26 | 80.29% | 🇺🇸 USA |